Importantly, the frequency of EGFR ex20ins observed in datasets that utilize NGS on tumour biopsies (GENIE and FoundationInsights) was generally consistent with that observed using liquid biopsies (GuardantINFORM), suggesting that both testing methods could accurately identify the diverse range of these mutations. The gene discussed is EGFR; the disease is neoplasm.